Venclexta

Overview

venetoclax

BCL-2 inhibitor

• CYP3A4 substrate
• P-gp substrate
• CYP2C9 inhibitor, weak
• P-gp inhibitor, weak
• immunomodulatory effects
• myelosuppressive oncologic agent

Contraindicated

• adagrasib
Venclexta (venetoclax)

+

adagrasib

1 interaction

Contraindicated

venetoclax + adagrasib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• adenovirus vaccine, live
Venclexta (venetoclax)

+

adenovirus vaccine, live

1 interaction

Contraindicated

venetoclax + adenovirus vaccine, live

contraindicated; vaccinate at least 4wk before or 6mo after venetoclax tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• atazanavir
Venclexta (venetoclax)

+

atazanavir

1 interaction

Contraindicated

venetoclax + atazanavir

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• BCG live intravesical
Venclexta (venetoclax)

+

BCG live intravesical

1 interaction

Contraindicated

venetoclax + BCG live intravesical

contraindicated: combo may incr. risk of disseminated BCG infection; may decr. immune response (immunosuppressive effects)

• ceritinib
Venclexta (venetoclax)

+

ceritinib

1 interaction

Contraindicated

venetoclax + ceritinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• chikungunya vaccine, live
Venclexta (venetoclax)

+

chikungunya vaccine, live

1 interaction

Contraindicated

venetoclax + chikungunya vaccine, live

contraindicated; vaccinate at least 4wk before or 6mo after venetoclax tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• chloramphenicol
Venclexta (venetoclax)

+

chloramphenicol

1 interaction

Contraindicated

venetoclax + chloramphenicol

use alternative or monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, additive effects)

• cholera vaccine, live
Venclexta (venetoclax)

+

cholera vaccine, live

1 interaction

Contraindicated

venetoclax + cholera vaccine, live

contraindicated; vaccinate at least 4wk before or 6mo after venetoclax tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• clarithromycin
Venclexta (venetoclax)

+

clarithromycin

1 interaction

Contraindicated

venetoclax + clarithromycin

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• cobicistat
Venclexta (venetoclax)

+

cobicistat

1 interaction

Contraindicated

venetoclax + cobicistat

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• colchicine
Venclexta (venetoclax)

+

colchicine

1 interaction

Contraindicated

venetoclax + colchicine

CV RISK REDUCTION: monitor CBC; consider monitoring CK, myopathy s/sx; give colchicine at least 6h before venetoclax; GOUT OR FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, monitor CBC and give colchicine at least 6h before venetoclax; consider decr. colchicine dose during and x14 days after venetoclax: combo may incr. colchicine levels, risk of myelosuppression, myopathy, rhabdomyolysis, other life-threatening toxicity (gut P-gp-mediated transport inhibited, additive effects)

• dengue vaccine, live
Venclexta (venetoclax)

+

dengue vaccine, live

1 interaction

Contraindicated

venetoclax + dengue vaccine, live

contraindicated; vaccinate at least 4wk before or 6mo after venetoclax tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• idelalisib
Venclexta (venetoclax)

+

idelalisib

1 interaction

Contraindicated

venetoclax + idelalisib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• influenza nasal vaccine, live
Venclexta (venetoclax)

+

influenza nasal vaccine, live

1 interaction

Contraindicated

venetoclax + influenza nasal vaccine, live

contraindicated; vaccinate at least 4wk before or 6mo after venetoclax tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• itraconazole
Venclexta (venetoclax)

+

itraconazole

1 interaction

Contraindicated

venetoclax + itraconazole

during and x2wk after itraconazole tx, monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• ketoconazole
Venclexta (venetoclax)

+

ketoconazole

1 interaction

Contraindicated

venetoclax + ketoconazole

during and up to 1wk after ketoconazole tx, monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• levoketoconazole
Venclexta (venetoclax)

+

levoketoconazole

1 interaction

Contraindicated

venetoclax + levoketoconazole

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• lonafarnib
Venclexta (venetoclax)

+

lonafarnib

1 interaction

Contraindicated

venetoclax + lonafarnib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

• lopinavir/ritonavir
Venclexta (venetoclax)

+

lopinavir/ ritonavir

1 interaction

Contraindicated

venetoclax + lopinavir/ ritonavir

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• measles/mumps/rubella vaccine, live
Venclexta (venetoclax)

+

measles/ mumps/ rubella vaccine, live

1 interaction

Contraindicated

venetoclax + measles/ mumps/ rubella vaccine, live

contraindicated; vaccinate at least 4wk before or 6mo after venetoclax tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• mifepristone
Venclexta (venetoclax)

+

mifepristone

1 interaction

Contraindicated

venetoclax + mifepristone

during and x14 days after daily mifepristone use, monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• nefazodone
Venclexta (venetoclax)

+

nefazodone

1 interaction

Contraindicated

venetoclax + nefazodone

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• nelfinavir
Venclexta (venetoclax)

+

nelfinavir

1 interaction

Contraindicated

venetoclax + nelfinavir

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• posaconazole
Venclexta (venetoclax)

+

posaconazole

1 interaction

Contraindicated

venetoclax + posaconazole

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• ribociclib
Venclexta (venetoclax)

+

ribociclib

1 interaction

Contraindicated

venetoclax + ribociclib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• ritonavir
Venclexta (venetoclax)

+

ritonavir

1 interaction

Contraindicated

venetoclax + ritonavir

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• rotavirus vaccine, live
Venclexta (venetoclax)

+

rotavirus vaccine, live

1 interaction

Contraindicated

venetoclax + rotavirus vaccine, live

contraindicated; vaccinate at least 4wk before or 6mo after venetoclax tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• smallpox vaccine, live
Venclexta (venetoclax)

+

smallpox vaccine, live

1 interaction

Contraindicated

venetoclax + smallpox vaccine, live

contraindicated; vaccinate at least 4wk before or 6mo after venetoclax tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• talimogene laherparepvec
Venclexta (venetoclax)

+

talimogene laherparepvec

1 interaction

Contraindicated

venetoclax + talimogene laherparepvec

contraindicated: combo may incr. risk of disseminated herpetic infection; may decr. immune response (immunosuppressive effects)

• tipranavir
Venclexta (venetoclax)

+

tipranavir

1 interaction

Contraindicated

venetoclax + tipranavir

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• tucatinib
Venclexta (venetoclax)

+

tucatinib

1 interaction

Contraindicated

venetoclax + tucatinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• typhoid vaccine, live
Venclexta (venetoclax)

+

typhoid vaccine, live

1 interaction

Contraindicated

venetoclax + typhoid vaccine, live

contraindicated; vaccinate at least 4wk before or 6mo after venetoclax tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• varicella vaccine, live
Venclexta (venetoclax)

+

varicella vaccine, live

1 interaction

Contraindicated

venetoclax + varicella vaccine, live

contraindicated; vaccinate at least 4wk before or 6mo after venetoclax tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• voriconazole
Venclexta (venetoclax)

+

voriconazole

1 interaction

Contraindicated

venetoclax + voriconazole

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• yellow fever vaccine, live
Venclexta (venetoclax)

+

yellow fever vaccine, live

1 interaction

Contraindicated

venetoclax + yellow fever vaccine, live

contraindicated; vaccinate at least 4wk before or 6mo after venetoclax tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

Avoid/Use Alternative

• abrocitinib
Venclexta (venetoclax)

+

abrocitinib

1 interaction

Avoid/Use Alternative

venetoclax + abrocitinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited, additive effects)

• aficamten
Venclexta (venetoclax)

+

aficamten

1 interaction

Avoid/Use Alternative

venetoclax + aficamten

monitor cardiac fxn (incl. LVEF), CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. levels of both drugs, risk of cardiotoxicity, serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• amiodarone
Venclexta (venetoclax)

+

amiodarone

1 interaction

Avoid/Use Alternative

venetoclax + amiodarone

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• apalutamide
Venclexta (venetoclax)

+

apalutamide

1 interaction

Avoid/Use Alternative

venetoclax + apalutamide

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• apixaban
Venclexta (venetoclax)

+

apixaban

1 interaction

Avoid/Use Alternative

venetoclax + apixaban

monitor bleeding s/sx; give apixaban at least 6h before venetoclax; ADULT PTS: if also combined w/ strong CYP3A4 inhibitor, decr. apixaban 5mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: if also combined w/ strong CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (gut P-gp-mediated transport inhibited)

• aprepitant
Venclexta (venetoclax)

+

aprepitant

1 interaction

Avoid/Use Alternative

venetoclax + aprepitant

if aprepitant 3-day regimen, monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%; aprepitant single dose-regimen OK: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• asciminib
Venclexta (venetoclax)

+

asciminib

1 interaction

Avoid/Use Alternative

venetoclax + asciminib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport possibly inhibited)

• avacopan
Venclexta (venetoclax)

+

avacopan

1 interaction

Avoid/Use Alternative

venetoclax + avacopan

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, additive effects)

• belumosudil
Venclexta (venetoclax)

+

belumosudil

1 interaction

Avoid/Use Alternative

venetoclax + belumosudil

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• berotralstat
Venclexta (venetoclax)

+

berotralstat

1 interaction

Avoid/Use Alternative

venetoclax + berotralstat

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• bisoprolol
Venclexta (venetoclax)

+

bisoprolol

1 interaction

Avoid/Use Alternative

venetoclax + bisoprolol

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• bosentan
Venclexta (venetoclax)

+

bosentan

1 interaction

Avoid/Use Alternative

venetoclax + bosentan

avoid combo: combo may incr. bosentan levels, risk of adverse effects; may decr. venetoclax levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• brigatinib
Venclexta (venetoclax)

+

brigatinib

1 interaction

Avoid/Use Alternative

venetoclax + brigatinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. or decr. venetoclax levels, incr. risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects or decr. efficacy (P-gp-mediated transport possibly inhibited, hepatic metabolism induced)

• butalbital
Venclexta (venetoclax)

+

butalbital

1 interaction

Avoid/Use Alternative

venetoclax + butalbital

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• canagliflozin
Venclexta (venetoclax)

+

canagliflozin

1 interaction

Avoid/Use Alternative

venetoclax + canagliflozin

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• cannabidiol
Venclexta (venetoclax)

+

cannabidiol

1 interaction

Avoid/Use Alternative

venetoclax + cannabidiol

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (gut P-gp-mediated transport inhibited)

• capmatinib
Venclexta (venetoclax)

+

capmatinib

1 interaction

Avoid/Use Alternative

venetoclax + capmatinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• captopril
Venclexta (venetoclax)

+

captopril

1 interaction

Avoid/Use Alternative

venetoclax + captopril

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• carbamazepine
Venclexta (venetoclax)

+

carbamazepine

1 interaction

Avoid/Use Alternative

venetoclax + carbamazepine

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• carvedilol
Venclexta (venetoclax)

+

carvedilol

1 interaction

Avoid/Use Alternative

venetoclax + carvedilol

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• cenobamate
Venclexta (venetoclax)

+

cenobamate

1 interaction

Avoid/Use Alternative

venetoclax + cenobamate

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• cimetidine
Venclexta (venetoclax)

+

cimetidine

1 interaction

Avoid/Use Alternative

venetoclax + cimetidine

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• ciprofloxacin
Venclexta (venetoclax)

+

ciprofloxacin

1 interaction

Avoid/Use Alternative

venetoclax + ciprofloxacin

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• cladribine oral
Venclexta (venetoclax)

+

cladribine oral

1 interaction

Avoid/Use Alternative

venetoclax + cladribine oral

use alternative or monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• clofazimine
Venclexta (venetoclax)

+

clofazimine

1 interaction

Avoid/Use Alternative

venetoclax + clofazimine

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• conivaptan
Venclexta (venetoclax)

+

conivaptan

1 interaction

Avoid/Use Alternative

venetoclax + conivaptan

during and x7 days after conivaptan tx, monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• crizotinib
Venclexta (venetoclax)

+

crizotinib

1 interaction

Avoid/Use Alternative

venetoclax + crizotinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• cyclosporine
Venclexta (venetoclax)

+

cyclosporine

1 interaction

Avoid/Use Alternative

venetoclax + cyclosporine

monitor cyclosporine levels, renal fxn, CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%; give oral cyclosporine at least 6h before venetoclax: combo may incr. levels of both drugs, risk of serious infection, myelosuppression, tumor lysis syndrome, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, gut P-gp-mediated transport inhibited, additive effects)

• dabigatran
Venclexta (venetoclax)

+

dabigatran

1 interaction

Avoid/Use Alternative

venetoclax + dabigatran

ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; otherwise, give dabigatran at least 6h before venetoclax; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; otherwise, give dabigatran at least 6h before venetoclax: combo may incr. dabigatran levels, risk of bleeding (including life-threatening), other adverse effects (gut P-gp-mediated transport inhibited)

• dabrafenib
Venclexta (venetoclax)

+

dabrafenib

1 interaction

Avoid/Use Alternative

venetoclax + dabrafenib

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• danazol
Venclexta (venetoclax)

+

danazol

1 interaction

Avoid/Use Alternative

venetoclax + danazol

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• danicopan
Venclexta (venetoclax)

+

danicopan

1 interaction

Avoid/Use Alternative

venetoclax + danicopan

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited, additive effects)

• daridorexant
Venclexta (venetoclax)

+

daridorexant

1 interaction

Avoid/Use Alternative

venetoclax + daridorexant

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• darunavir
Venclexta (venetoclax)

+

darunavir

1 interaction

Avoid/Use Alternative

venetoclax + darunavir

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• deferiprone
Venclexta (venetoclax)

+

deferiprone

1 interaction

Avoid/Use Alternative

venetoclax + deferiprone

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• dexrazoxane
Venclexta (venetoclax)

+

dexrazoxane

1 interaction

Avoid/Use Alternative

venetoclax + dexrazoxane

monitor CBC if anthracycline extravasation or doxorubicin cardioprotective use; otherwise, avoid combo: combo may incr. risk of myelosuppression; may decr. efficacy of cancer chemo (additive effects; mechanism unknown)

• diltiazem
Venclexta (venetoclax)

+

diltiazem

1 interaction

Avoid/Use Alternative

venetoclax + diltiazem

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• diosmin
Venclexta (venetoclax)

+

diosmin

1 interaction

Avoid/Use Alternative

venetoclax + diosmin

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• dronedarone
Venclexta (venetoclax)

+

dronedarone

1 interaction

Avoid/Use Alternative

venetoclax + dronedarone

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• duvelisib
Venclexta (venetoclax)

+

duvelisib

1 interaction

Avoid/Use Alternative

venetoclax + duvelisib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• efavirenz
Venclexta (venetoclax)

+

efavirenz

1 interaction

Avoid/Use Alternative

venetoclax + efavirenz

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• elacestrant
Venclexta (venetoclax)

+

elacestrant

1 interaction

Avoid/Use Alternative

venetoclax + elacestrant

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• elagolix
Venclexta (venetoclax)

+

elagolix

1 interaction

Avoid/Use Alternative

venetoclax + elagolix

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. or decr. venetoclax levels, incr. risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• elexacaftor/tezacaftor/ivacaftor
Venclexta (venetoclax)

+

elexacaftor/ tezacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

venetoclax + elexacaftor/ tezacaftor/ ivacaftor

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• eliglustat
Venclexta (venetoclax)

+

eliglustat

1 interaction

Avoid/Use Alternative

venetoclax + eliglustat

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• enasidenib
Venclexta (venetoclax)

+

enasidenib

1 interaction

Avoid/Use Alternative

venetoclax + enasidenib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or venetoclax dose adjustment; AML: consider venetoclax dose adjustment: combo may incr. or decr. venetoclax levels, incr. risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• encorafenib
Venclexta (venetoclax)

+

encorafenib

1 interaction

Avoid/Use Alternative

venetoclax + encorafenib

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• ensartinib
Venclexta (venetoclax)

+

ensartinib

1 interaction

Avoid/Use Alternative

venetoclax + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• entrectinib
Venclexta (venetoclax)

+

entrectinib

1 interaction

Avoid/Use Alternative

venetoclax + entrectinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• enzalutamide
Venclexta (venetoclax)

+

enzalutamide

1 interaction

Avoid/Use Alternative

venetoclax + enzalutamide

avoid combo: combo may incr. or decr. venetoclax levels, incr. risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• erdafitinib
Venclexta (venetoclax)

+

erdafitinib

1 interaction

Avoid/Use Alternative

venetoclax + erdafitinib

monitor CBC, tumor lysis syndrome s/sx; separate admin by at least 6h; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport possibly inhibited)

• erythromycin
Venclexta (venetoclax)

+

erythromycin

1 interaction

Avoid/Use Alternative

venetoclax + erythromycin

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• etrasimod
Venclexta (venetoclax)

+

etrasimod

1 interaction

Avoid/Use Alternative

venetoclax + etrasimod

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• etravirine
Venclexta (venetoclax)

+

etravirine

1 interaction

Avoid/Use Alternative

venetoclax + etravirine

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• fedratinib
Venclexta (venetoclax)

+

fedratinib

1 interaction

Avoid/Use Alternative

venetoclax + fedratinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• felodipine
Venclexta (venetoclax)

+

felodipine

1 interaction

Avoid/Use Alternative

venetoclax + felodipine

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• fexinidazole
Venclexta (venetoclax)

+

fexinidazole

1 interaction

Avoid/Use Alternative

venetoclax + fexinidazole

avoid combo: combo may decr. venetoclax levels, efficacy; may incr. risk of myelosuppression (hepatic metabolism induced; additive effects)

• flibanserin
Venclexta (venetoclax)

+

flibanserin

1 interaction

Avoid/Use Alternative

venetoclax + flibanserin

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• fluconazole
Venclexta (venetoclax)

+

fluconazole

1 interaction

Avoid/Use Alternative

venetoclax + fluconazole

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• fluvoxamine
Venclexta (venetoclax)

+

fluvoxamine

1 interaction

Avoid/Use Alternative

venetoclax + fluvoxamine

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• fosamprenavir
Venclexta (venetoclax)

+

fosamprenavir

1 interaction

Avoid/Use Alternative

venetoclax + fosamprenavir

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. or decr. venetoclax levels, incr. risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects or decr. efficacy (hepatic metabolism altered)

• fosphenytoin
Venclexta (venetoclax)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

venetoclax + fosphenytoin

avoid combo: combo may incr. phenytoin levels, risk of toxicity; may decr. venetoclax levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• fostamatinib
Venclexta (venetoclax)

+

fostamatinib

1 interaction

Avoid/Use Alternative

venetoclax + fostamatinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

• ganciclovir
Venclexta (venetoclax)

+

ganciclovir

1 interaction

Avoid/Use Alternative

venetoclax + ganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• gilteritinib
Venclexta (venetoclax)

+

gilteritinib

1 interaction

Avoid/Use Alternative

venetoclax + gilteritinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport possibly inhibited)

• ginkgo
Venclexta (venetoclax)

+

ginkgo

1 interaction

Avoid/Use Alternative

venetoclax + ginkgo

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. or decr. venetoclax levels, incr. risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects or decr. efficacy (hepatic metabolism altered, P-gp-mediated transport inhibited)

• glecaprevir
Venclexta (venetoclax)

+

glecaprevir

1 interaction

Avoid/Use Alternative

venetoclax + glecaprevir

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%; give glecaprevir at least 6h before venetoclax: combo may incr. levels of both drugs, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• grapefruit
Venclexta (venetoclax)

+

grapefruit

1 interaction

Avoid/Use Alternative

venetoclax + grapefruit

avoid grapefruit juice: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (GI metabolism inhibited)

• ibrutinib
Venclexta (venetoclax)

+

ibrutinib

1 interaction

Avoid/Use Alternative

venetoclax + ibrutinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (gut P-gp-mediated transport inhibited)

• imatinib
Venclexta (venetoclax)

+

imatinib

1 interaction

Avoid/Use Alternative

venetoclax + imatinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• imlunestrant
Venclexta (venetoclax)

+

imlunestrant

1 interaction

Avoid/Use Alternative

venetoclax + imlunestrant

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• indomethacin
Venclexta (venetoclax)

+

indomethacin

1 interaction

Avoid/Use Alternative

venetoclax + indomethacin

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• isavuconazonium
Venclexta (venetoclax)

+

isavuconazonium

1 interaction

Avoid/Use Alternative

venetoclax + isavuconazonium

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• istradefylline
Venclexta (venetoclax)

+

istradefylline

1 interaction

Avoid/Use Alternative

venetoclax + istradefylline

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• ivacaftor
Venclexta (venetoclax)

+

ivacaftor

1 interaction

Avoid/Use Alternative

venetoclax + ivacaftor

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• ivosidenib
Venclexta (venetoclax)

+

ivosidenib

1 interaction

Avoid/Use Alternative

venetoclax + ivosidenib

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• lapatinib
Venclexta (venetoclax)

+

lapatinib

1 interaction

Avoid/Use Alternative

venetoclax + lapatinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• ledipasvir
Venclexta (venetoclax)

+

ledipasvir

1 interaction

Avoid/Use Alternative

venetoclax + ledipasvir

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (gut P-gp-mediated transport inhibited)

• lefamulin
Venclexta (venetoclax)

+

lefamulin

1 interaction

Avoid/Use Alternative

venetoclax + lefamulin

ORAL LEFAMULIN: monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%; IV lefamulin use OK: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• lenacapavir
Venclexta (venetoclax)

+

lenacapavir

1 interaction

Avoid/Use Alternative

venetoclax + lenacapavir

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50% during and x9mo after lenacapavir tx; AML: decr. venetoclax dose by at least 50% during and x9mo after lenacapavir tx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• letermovir
Venclexta (venetoclax)

+

letermovir

1 interaction

Avoid/Use Alternative

venetoclax + letermovir

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• levacetylleucine
Venclexta (venetoclax)

+

levacetylleucine

1 interaction

Avoid/Use Alternative

venetoclax + levacetylleucine

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport possibly inhibited)

• lomitapide
Venclexta (venetoclax)

+

lomitapide

1 interaction

Avoid/Use Alternative

venetoclax + lomitapide

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, gut P-gp-mediated transport possibly inhibited)

• lorlatinib
Venclexta (venetoclax)

+

lorlatinib

1 interaction

Avoid/Use Alternative

venetoclax + lorlatinib

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• lumacaftor/ivacaftor
Venclexta (venetoclax)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

venetoclax + lumacaftor/ ivacaftor

avoid combo: combo may incr. or decr. venetoclax levels, incr. risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects or decr. efficacy (hepatic metabolism induced, P-gp-mediated transport inhibited)

• maribavir
Venclexta (venetoclax)

+

maribavir

1 interaction

Avoid/Use Alternative

venetoclax + maribavir

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• mavacamten
Venclexta (venetoclax)

+

mavacamten

1 interaction

Avoid/Use Alternative

venetoclax + mavacamten

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• mavorixafor
Venclexta (venetoclax)

+

mavorixafor

1 interaction

Avoid/Use Alternative

venetoclax + mavorixafor

monitor ECG, CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• methadone
Venclexta (venetoclax)

+

methadone

1 interaction

Avoid/Use Alternative

venetoclax + methadone

use alternative or monitor resp. rate, ECG, consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• milk thistle
Venclexta (venetoclax)

+

milk thistle

1 interaction

Avoid/Use Alternative

venetoclax + milk thistle

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• mirabegron
Venclexta (venetoclax)

+

mirabegron

1 interaction

Avoid/Use Alternative

venetoclax + mirabegron

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• mitapivat
Venclexta (venetoclax)

+

mitapivat

1 interaction

Avoid/Use Alternative

venetoclax + mitapivat

avoid combo: combo may incr. or decr. venetoclax levels, incr. risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects or decr. efficacy (hepatic metabolism induced, P-gp-mediated transport possibly inhibited)

• mitotane
Venclexta (venetoclax)

+

mitotane

1 interaction

Avoid/Use Alternative

venetoclax + mitotane

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• modafinil
Venclexta (venetoclax)

+

modafinil

1 interaction

Avoid/Use Alternative

venetoclax + modafinil

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• nafcillin
Venclexta (venetoclax)

+

nafcillin

1 interaction

Avoid/Use Alternative

venetoclax + nafcillin

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• naproxen
Venclexta (venetoclax)

+

naproxen

1 interaction

Avoid/Use Alternative

venetoclax + naproxen

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• neratinib
Venclexta (venetoclax)

+

neratinib

1 interaction

Avoid/Use Alternative

venetoclax + neratinib

avoid combo if also combined w/ mod-strong CYP3A4 inhibitor; otherwise, monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%; give neratinib at least 6h before venetoclax: combo may incr. levels of both drugs, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• netupitant
Venclexta (venetoclax)

+

netupitant

1 interaction

Avoid/Use Alternative

venetoclax + netupitant

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• nifedipine
Venclexta (venetoclax)

+

nifedipine

1 interaction

Avoid/Use Alternative

venetoclax + nifedipine

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• nilotinib
Venclexta (venetoclax)

+

nilotinib

1 interaction

Avoid/Use Alternative

venetoclax + nilotinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• nirogacestat
Venclexta (venetoclax)

+

nirogacestat

1 interaction

Avoid/Use Alternative

venetoclax + nirogacestat

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• osimertinib
Venclexta (venetoclax)

+

osimertinib

1 interaction

Avoid/Use Alternative

venetoclax + osimertinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• pacritinib
Venclexta (venetoclax)

+

pacritinib

1 interaction

Avoid/Use Alternative

venetoclax + pacritinib

avoid combo: combo may incr. or decr. venetoclax levels, incr. risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects or decr. efficacy (hepatic metabolism induced, P-gp-mediated transport inhibited)

• palifermin
Venclexta (venetoclax)

+

palifermin

1 interaction

Avoid/Use Alternative

venetoclax + palifermin

avoid palifermin admin. w/in 24h before, during tx, or w/in 24h after myelotoxic chemo; otherwise, caution advised: combo may incr. severity and duration of oral mucositis (antagonistic effects)

• paroxetine
Venclexta (venetoclax)

+

paroxetine

1 interaction

Avoid/Use Alternative

venetoclax + paroxetine

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• penicillamine
Venclexta (venetoclax)

+

penicillamine

1 interaction

Avoid/Use Alternative

venetoclax + penicillamine

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pentobarbital
Venclexta (venetoclax)

+

pentobarbital

1 interaction

Avoid/Use Alternative

venetoclax + pentobarbital

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• pexidartinib
Venclexta (venetoclax)

+

pexidartinib

1 interaction

Avoid/Use Alternative

venetoclax + pexidartinib

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• phenobarbital
Venclexta (venetoclax)

+

phenobarbital

1 interaction

Avoid/Use Alternative

venetoclax + phenobarbital

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• phenytoin
Venclexta (venetoclax)

+

phenytoin

1 interaction

Avoid/Use Alternative

venetoclax + phenytoin

avoid combo: combo may incr. phenytoin levels, risk of toxicity; may decr. venetoclax levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• pibrentasvir
Venclexta (venetoclax)

+

pibrentasvir

1 interaction

Avoid/Use Alternative

venetoclax + pibrentasvir

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%; give pibrentasvir at least 6h before venetoclax: combo may incr. levels of both drugs, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• pimecrolimus topical
Venclexta (venetoclax)

+

pimecrolimus topical

1 interaction

Avoid/Use Alternative

venetoclax + pimecrolimus topical

avoid combo: combo may incr. risk of serious infection (additive effects)

• pirtobrutinib
Venclexta (venetoclax)

+

pirtobrutinib

1 interaction

Avoid/Use Alternative

venetoclax + pirtobrutinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

• ponatinib
Venclexta (venetoclax)

+

ponatinib

1 interaction

Avoid/Use Alternative

venetoclax + ponatinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport possibly inhibited)

• pralsetinib
Venclexta (venetoclax)

+

pralsetinib

1 interaction

Avoid/Use Alternative

venetoclax + pralsetinib

use alternative or give pralsetinib at least 6h before venetoclax; if also combined w/ strong CYP3A4 inhibitor and unable to separate doses, consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd or 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• primaquine
Venclexta (venetoclax)

+

primaquine

1 interaction

Avoid/Use Alternative

venetoclax + primaquine

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• primidone
Venclexta (venetoclax)

+

primidone

1 interaction

Avoid/Use Alternative

venetoclax + primidone

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• propafenone
Venclexta (venetoclax)

+

propafenone

1 interaction

Avoid/Use Alternative

venetoclax + propafenone

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• quercetin
Venclexta (venetoclax)

+

quercetin

1 interaction

Avoid/Use Alternative

venetoclax + quercetin

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• quinidine (antiarrhythmic)
Venclexta (venetoclax)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

venetoclax + quinidine (antiarrhythmic)

monitor CBC, tumor lysis syndrome s/sx, quinidine levels, ECG; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%; give quinidine at least 6h before venetoclax: combo may incr. levels of both drugs, risk of serious infection, myelosuppression, tumor lysis syndrome, QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

• quinidine (CYP2D6 inhibitor)
Venclexta (venetoclax)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Avoid/Use Alternative

venetoclax + quinidine (CYP2D6 inhibitor)

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• quinine
Venclexta (venetoclax)

+

quinine

1 interaction

Avoid/Use Alternative

venetoclax + quinine

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• rabies vaccine
Venclexta (venetoclax)

+

rabies vaccine

1 interaction

Avoid/Use Alternative

venetoclax + rabies vaccine

if possible, avoid immunosuppressive tx or vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• radium Ra 223 dichloride
Venclexta (venetoclax)

+

radium Ra 223 dichloride

1 interaction

Avoid/Use Alternative

venetoclax + radium Ra 223 dichloride

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ranolazine
Venclexta (venetoclax)

+

ranolazine

1 interaction

Avoid/Use Alternative

venetoclax + ranolazine

monitor ECG, CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%; give ranolazine at least 6h before venetoclax: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• relugolix
Venclexta (venetoclax)

+

relugolix

1 interaction

Avoid/Use Alternative

venetoclax + relugolix

PROSTATE CANCER: may hold relugolix if venetoclax tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before venetoclax; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before venetoclax: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• remibrutinib
Venclexta (venetoclax)

+

remibrutinib

1 interaction

Avoid/Use Alternative

venetoclax + remibrutinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• repotrectinib
Venclexta (venetoclax)

+

repotrectinib

1 interaction

Avoid/Use Alternative

venetoclax + repotrectinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. venetoclax levels, efficacy (gut P-gp-mediated transport inhibited; hepatic metabolism induced)

• rifabutin
Venclexta (venetoclax)

+

rifabutin

1 interaction

Avoid/Use Alternative

venetoclax + rifabutin

avoid combo: combo may decr. venetoclax levels, efficacy; may incr. risk of myelosuppression (hepatic metabolism induced; additive effects)

• rifampin
Venclexta (venetoclax)

+

rifampin

1 interaction

Avoid/Use Alternative

venetoclax + rifampin

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• rifapentine
Venclexta (venetoclax)

+

rifapentine

1 interaction

Avoid/Use Alternative

venetoclax + rifapentine

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• rilzabrutinib
Venclexta (venetoclax)

+

rilzabrutinib

1 interaction

Avoid/Use Alternative

venetoclax + rilzabrutinib

ALL INDICATIONS: monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport possibly inhibited, additive effects)

• rivaroxaban
Venclexta (venetoclax)

+

rivaroxaban

1 interaction

Avoid/Use Alternative

venetoclax + rivaroxaban

avoid combo if also combined w/ strong CYP3A4 inhibitor; use alternative if CrCl <80 and combined w/ moderate CYP3A4 inhibitor; otherwise, monitor bleeding s/sx and give rivaroxaban at least 6h before venetoclax: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (gut P-gp-mediated transport inhibited)

• rolapitant
Venclexta (venetoclax)

+

rolapitant

1 interaction

Avoid/Use Alternative

venetoclax + rolapitant

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• ropeginterferon alfa-2b
Venclexta (venetoclax)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

venetoclax + ropeginterferon alfa-2b

use alternative or monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• rucaparib
Venclexta (venetoclax)

+

rucaparib

1 interaction

Avoid/Use Alternative

venetoclax + rucaparib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• sarecycline
Venclexta (venetoclax)

+

sarecycline

1 interaction

Avoid/Use Alternative

venetoclax + sarecycline

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• selpercatinib
Venclexta (venetoclax)

+

selpercatinib

1 interaction

Avoid/Use Alternative

venetoclax + selpercatinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• sevabertinib
Venclexta (venetoclax)

+

sevabertinib

1 interaction

Avoid/Use Alternative

venetoclax + sevabertinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• sorafenib
Venclexta (venetoclax)

+

sorafenib

1 interaction

Avoid/Use Alternative

venetoclax + sorafenib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport possibly inhibited)

• sotagliflozin
Venclexta (venetoclax)

+

sotagliflozin

1 interaction

Avoid/Use Alternative

venetoclax + sotagliflozin

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• sotorasib
Venclexta (venetoclax)

+

sotorasib

1 interaction

Avoid/Use Alternative

venetoclax + sotorasib

avoid combo: combo may incr. or decr. venetoclax levels, incr. risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• sparsentan
Venclexta (venetoclax)

+

sparsentan

1 interaction

Avoid/Use Alternative

venetoclax + sparsentan

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport possibly inhibited)

• St. John's wort
Venclexta (venetoclax)

+

St. John's wort

1 interaction

Avoid/Use Alternative

venetoclax + St. John's wort

avoid combo: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• stiripentol
Venclexta (venetoclax)

+

stiripentol

1 interaction

Avoid/Use Alternative

venetoclax + stiripentol

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. or decr. venetoclax levels, incr. risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects or decr. efficacy (hepatic metabolism possibly altered, P-gp-mediated transport possibly inhibited, additive effects)

• sunvozertinib
Venclexta (venetoclax)

+

sunvozertinib

1 interaction

Avoid/Use Alternative

venetoclax + sunvozertinib

consider alternative: combo may incr. venetoclax levels, incr. risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• suvorexant
Venclexta (venetoclax)

+

suvorexant

1 interaction

Avoid/Use Alternative

venetoclax + suvorexant

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (gut P-gp-mediated transport inhibited)

• tacrolimus
Venclexta (venetoclax)

+

tacrolimus

1 interaction

Avoid/Use Alternative

venetoclax + tacrolimus

ALL INDICATIONS: monitor tacrolimus levels, ECG, renal fxn, CBC, tumor lysis syndrome s/sx; give oral tacrolimus at least 6h before venetoclax; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (gut P-gp-mediated transport inhibited, additive effects)

• talazoparib
Venclexta (venetoclax)

+

talazoparib

1 interaction

Avoid/Use Alternative

venetoclax + talazoparib

use alternative or monitor CBC; give talazoparib at least 6h before venetoclax: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (gut P-gp-mediated transport inhibited)

• telmisartan
Venclexta (venetoclax)

+

telmisartan

1 interaction

Avoid/Use Alternative

venetoclax + telmisartan

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• temsirolimus
Venclexta (venetoclax)

+

temsirolimus

1 interaction

Avoid/Use Alternative

venetoclax + temsirolimus

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport possibly inhibited)

• tenofovir disoproxil
Venclexta (venetoclax)

+

tenofovir disoproxil

1 interaction

Avoid/Use Alternative

venetoclax + tenofovir disoproxil

use alternative or monitor renal fxn; give tenofovir disoproxil at least 6h before venetoclax: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited)

• tepotinib
Venclexta (venetoclax)

+

tepotinib

1 interaction

Avoid/Use Alternative

venetoclax + tepotinib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• tezacaftor/ivacaftor
Venclexta (venetoclax)

+

tezacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

venetoclax + tezacaftor/ ivacaftor

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• ticagrelor
Venclexta (venetoclax)

+

ticagrelor

1 interaction

Avoid/Use Alternative

venetoclax + ticagrelor

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• tolvaptan
Venclexta (venetoclax)

+

tolvaptan

1 interaction

Avoid/Use Alternative

venetoclax + tolvaptan

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• topotecan
Venclexta (venetoclax)

+

topotecan

1 interaction

Avoid/Use Alternative

venetoclax + topotecan

avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut P-gp-mediated transport inhibited)

• trazodone
Venclexta (venetoclax)

+

trazodone

1 interaction

Avoid/Use Alternative

venetoclax + trazodone

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• trimethoprim
Venclexta (venetoclax)

+

trimethoprim

1 interaction

Avoid/Use Alternative

venetoclax + trimethoprim

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited, additive effects)

• trofinetide
Venclexta (venetoclax)

+

trofinetide

1 interaction

Avoid/Use Alternative

venetoclax + trofinetide

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (GI metabolism inhibited, gut P-gp-mediated transport inhibited)

• turmeric
Venclexta (venetoclax)

+

turmeric

1 interaction

Avoid/Use Alternative

venetoclax + turmeric

monitor CBC, tumor lysis syndrome s/sx w/ oral turmeric; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (gut P-gp-mediated transport inhibited)

• uridine triacetate
Venclexta (venetoclax)

+

uridine triacetate

1 interaction

Avoid/Use Alternative

venetoclax + uridine triacetate

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (gut P-gp-mediated transport inhibited)

• valbenazine
Venclexta (venetoclax)

+

valbenazine

1 interaction

Avoid/Use Alternative

venetoclax + valbenazine

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• valganciclovir
Venclexta (venetoclax)

+

valganciclovir

1 interaction

Avoid/Use Alternative

venetoclax + valganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• vandetanib
Venclexta (venetoclax)

+

vandetanib

1 interaction

Avoid/Use Alternative

venetoclax + vandetanib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• vanzacaftor/tezacaftor/deutivacaftor
Venclexta (venetoclax)

+

vanzacaftor/ tezacaftor/ deutivacaftor

1 interaction

Avoid/Use Alternative

venetoclax + vanzacaftor/ tezacaftor/ deutivacaftor

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport possibly inhibited)

• velpatasvir
Venclexta (venetoclax)

+

velpatasvir

1 interaction

Avoid/Use Alternative

venetoclax + velpatasvir

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (gut P-gp-mediated transport inhibited)

• vemurafenib
Venclexta (venetoclax)

+

vemurafenib

1 interaction

Avoid/Use Alternative

venetoclax + vemurafenib

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. or decr. venetoclax levels, incr. risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• verapamil
Venclexta (venetoclax)

+

verapamil

1 interaction

Avoid/Use Alternative

venetoclax + verapamil

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

• vimseltinib
Venclexta (venetoclax)

+

vimseltinib

1 interaction

Avoid/Use Alternative

venetoclax + vimseltinib

monitor CBC, tumor lysis syndrome s/sx; give vimseltinib at least 4h before venetoclax; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• voclosporin
Venclexta (venetoclax)

+

voclosporin

1 interaction

Avoid/Use Alternative

venetoclax + voclosporin

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited, additive effects)

• voxilaprevir
Venclexta (venetoclax)

+

voxilaprevir

1 interaction

Avoid/Use Alternative

venetoclax + voxilaprevir

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (gut P-gp-mediated transport inhibited)

• xanomeline
Venclexta (venetoclax)

+

xanomeline

1 interaction

Avoid/Use Alternative

venetoclax + xanomeline

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (GI metabolism possibly inhibited, gut P-gp-mediated transport possibly inhibited)

• zonisamide
Venclexta (venetoclax)

+

zonisamide

1 interaction

Avoid/Use Alternative

venetoclax + zonisamide

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport possibly inhibited)

Monitor/Modify Tx

• afatinib
Venclexta (venetoclax)

+

afatinib

1 interaction

Monitor/Modify Tx

venetoclax + afatinib

give afatinib at least 6h before venetoclax; decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• albendazole
Venclexta (venetoclax)

+

albendazole

1 interaction

Monitor/Modify Tx

venetoclax + albendazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• alemtuzumab
Venclexta (venetoclax)

+

alemtuzumab

1 interaction

Monitor/Modify Tx

venetoclax + alemtuzumab

monitor CBC; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of serious infection, myelosuppression (additive effects)

• allopurinol
Venclexta (venetoclax)

+

allopurinol

1 interaction

Monitor/Modify Tx

venetoclax + allopurinol

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• alprazolam
Venclexta (venetoclax)

+

alprazolam

1 interaction

Monitor/Modify Tx

venetoclax + alprazolam

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• amlodipine
Venclexta (venetoclax)

+

amlodipine

1 interaction

Monitor/Modify Tx

venetoclax + amlodipine

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• anthrax vaccine
Venclexta (venetoclax)

+

anthrax vaccine

1 interaction

Monitor/Modify Tx

venetoclax + anthrax vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anti-thymocyte globulin
Venclexta (venetoclax)

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

venetoclax + anti-thymocyte globulin

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• atidarsagene autotemcel
Venclexta (venetoclax)

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

venetoclax + atidarsagene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of serious infection, myelosuppression (additive effects)

• atorvastatin
Venclexta (venetoclax)

+

atorvastatin

1 interaction

Monitor/Modify Tx

venetoclax + atorvastatin

monitor CK, myopathy sx, CBC, tumor lysis syndrome s/sx; give atorvastatin at least 6h before venetoclax: combo may incr. levels of both drugs, risk of myopathy, rhabdomyolysis, serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, gut P-gp-mediated transport inhibited)

• auranofin
Venclexta (venetoclax)

+

auranofin

1 interaction

Monitor/Modify Tx

venetoclax + auranofin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• azathioprine
Venclexta (venetoclax)

+

azathioprine

1 interaction

Monitor/Modify Tx

venetoclax + azathioprine

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• azithromycin
Venclexta (venetoclax)

+

azithromycin

1 interaction

Monitor/Modify Tx

venetoclax + azithromycin

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport possibly inhibited)

• balsalazide
Venclexta (venetoclax)

+

balsalazide

1 interaction

Monitor/Modify Tx

venetoclax + balsalazide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• baricitinib
Venclexta (venetoclax)

+

baricitinib

1 interaction

Monitor/Modify Tx

venetoclax + baricitinib

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• benznidazole
Venclexta (venetoclax)

+

benznidazole

1 interaction

Monitor/Modify Tx

venetoclax + benznidazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• berberine
Venclexta (venetoclax)

+

berberine

1 interaction

Monitor/Modify Tx

venetoclax + berberine

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• betibeglogene autotemcel
Venclexta (venetoclax)

+

betibeglogene autotemcel

1 interaction

Monitor/Modify Tx

venetoclax + betibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• bicalutamide
Venclexta (venetoclax)

+

bicalutamide

1 interaction

Monitor/Modify Tx

venetoclax + bicalutamide

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• capivasertib
Venclexta (venetoclax)

+

capivasertib

1 interaction

Monitor/Modify Tx

venetoclax + capivasertib

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• celecoxib
Venclexta (venetoclax)

+

celecoxib

1 interaction

Monitor/Modify Tx

venetoclax + celecoxib

monitor bleeding s/sx: combo may incr. celecoxib levels, risk of GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• chikungunya vaccine
Venclexta (venetoclax)

+

chikungunya vaccine

1 interaction

Monitor/Modify Tx

venetoclax + chikungunya vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• chlorzoxazone
Venclexta (venetoclax)

+

chlorzoxazone

1 interaction

Monitor/Modify Tx

venetoclax + chlorzoxazone

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• cidofovir
Venclexta (venetoclax)

+

cidofovir

1 interaction

Monitor/Modify Tx

venetoclax + cidofovir

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cilostazol
Venclexta (venetoclax)

+

cilostazol

1 interaction

Monitor/Modify Tx

venetoclax + cilostazol

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• clotrimazole oropharyngeal
Venclexta (venetoclax)

+

clotrimazole oropharyngeal

1 interaction

Monitor/Modify Tx

venetoclax + clotrimazole oropharyngeal

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• clozapine
Venclexta (venetoclax)

+

clozapine

1 interaction

Monitor/Modify Tx

venetoclax + clozapine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• copper histidinate
Venclexta (venetoclax)

+

copper histidinate

1 interaction

Monitor/Modify Tx

venetoclax + copper histidinate

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• COVID-19 vaccine
Venclexta (venetoclax)

+

COVID-19 vaccine

1 interaction

Monitor/Modify Tx

venetoclax + COVID-19 vaccine

if possible, vaccinate at least 4wk before or 3-6mo after venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cranberry
Venclexta (venetoclax)

+

cranberry

1 interaction

Monitor/Modify Tx

venetoclax + cranberry

monitor CBC, tumor lysis syndrome s/sx, especially w/ large amounts of cranberry: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (GI metabolism inhibited)

• cyclophosphamide
Venclexta (venetoclax)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

venetoclax + cyclophosphamide

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• dapsone
Venclexta (venetoclax)

+

dapsone

1 interaction

Monitor/Modify Tx

venetoclax + dapsone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• darolutamide
Venclexta (venetoclax)

+

darolutamide

1 interaction

Monitor/Modify Tx

venetoclax + darolutamide

give darolutamide at least 6h before venetoclax: combo may incr. darolutamide levels, risk of adverse effects; may decr. venetoclax levels, efficacy (gut P-gp-mediated transport inhibited; hepatic metabolism induced)

• deferasirox
Venclexta (venetoclax)

+

deferasirox

1 interaction

Monitor/Modify Tx

venetoclax + deferasirox

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• deuruxolitinib
Venclexta (venetoclax)

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

venetoclax + deuruxolitinib

monitor CBC, thrombosis s/sx: combo may incr. deuruxolitinib levels, risk of serious infection, thromboembolism, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• diclofenac
Venclexta (venetoclax)

+

diclofenac

1 interaction

Monitor/Modify Tx

venetoclax + diclofenac

monitor bleeding s/sx; use lowest effective diclofenac dose, shortest duration of concomitant tx: combo may incr. diclofenac levels, risk of GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• digoxin
Venclexta (venetoclax)

+

digoxin

1 interaction

Monitor/Modify Tx

venetoclax + digoxin

monitor digoxin levels, HR; decr. digoxin frequency or dose by 15-30%; give oral digoxin at least 6h before venetoclax: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (gut P-gp-mediated transport inhibited)

• diphtheria/tetanus vaccine
Venclexta (venetoclax)

+

diphtheria/ tetanus vaccine

1 interaction

Monitor/Modify Tx

venetoclax + diphtheria/ tetanus vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• diphtheria/tetanus/pertussis vaccine
Venclexta (venetoclax)

+

diphtheria/ tetanus/ pertussis vaccine

1 interaction

Monitor/Modify Tx

venetoclax + diphtheria/ tetanus/ pertussis vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ebola vaccine, live
Venclexta (venetoclax)

+

ebola vaccine, live

1 interaction

Monitor/Modify Tx

venetoclax + ebola vaccine, live

consider vaccinating at least 4wk before or 6mo after venetoclax tx: combo may result in inadequate vaccine response; may incr. risk of mild vesicular stomatitis virus infection (immunosuppressive effects, recombinant vaccine with vesicular stomatitis virus vector)

• edoxaban
Venclexta (venetoclax)

+

edoxaban

1 interaction

Monitor/Modify Tx

venetoclax + edoxaban

monitor bleeding s/sx; give edoxaban at least 6h before venetoclax: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (gut P-gp-mediated transport inhibited)

• efbemalenograstim alfa
Venclexta (venetoclax)

+

efbemalenograstim alfa

1 interaction

Monitor/Modify Tx

venetoclax + efbemalenograstim alfa

admin. efbemalenograstim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. efbemalenograstim efficacy (antagonistic effects)

• eflapegrastim (G-CSF)
Venclexta (venetoclax)

+

eflapegrastim (G-CSF)

1 interaction

Monitor/Modify Tx

venetoclax + eflapegrastim (G-CSF)

admin. eflapegrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. eflapegrastim efficacy (antagonistic effects)

• elinzanetant
Venclexta (venetoclax)

+

elinzanetant

1 interaction

Monitor/Modify Tx

venetoclax + elinzanetant

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• elivaldogene autotemcel
Venclexta (venetoclax)

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

venetoclax + elivaldogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, serious infection (additive effects)

• ethinyl estradiol (contraceptive)
Venclexta (venetoclax)

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

venetoclax + ethinyl estradiol (contraceptive)

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• etuvetidigene autotemcel
Venclexta (venetoclax)

+

etuvetidigene autotemcel

1 interaction

Monitor/Modify Tx

venetoclax + etuvetidigene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of serious infection, myelosuppression, bleeding (additive effects)

• everolimus
Venclexta (venetoclax)

+

everolimus

1 interaction

Monitor/Modify Tx

venetoclax + everolimus

TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC, tumor lysis syndrome s/sx; OTHER INDICATIONS: monitor CBC, tumor lysis syndrome s/sx; give everolimus at least 6h before venetoclax: combo may incr. levels of both drugs, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, gut P-gp-mediated transport inhibited, additive effects)

• exagamglogene autotemcel
Venclexta (venetoclax)

+

exagamglogene autotemcel

1 interaction

Monitor/Modify Tx

venetoclax + exagamglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• filgrastim (G-CSF)
Venclexta (venetoclax)

+

filgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

venetoclax + filgrastim (G-CSF)

admin. filgrastim at least 24h before or after myelosuppressive chemo: combo may decr. filgrastim efficacy (antagonistic effects)

• finerenone
Venclexta (venetoclax)

+

finerenone

1 interaction

Monitor/Modify Tx

venetoclax + finerenone

monitor CBC, tumor lysis syndrome s/sx if on finerenone 40 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• flucytosine
Venclexta (venetoclax)

+

flucytosine

1 interaction

Monitor/Modify Tx

venetoclax + flucytosine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fluphenazine
Venclexta (venetoclax)

+

fluphenazine

1 interaction

Monitor/Modify Tx

venetoclax + fluphenazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fluvastatin
Venclexta (venetoclax)

+

fluvastatin

1 interaction

Monitor/Modify Tx

venetoclax + fluvastatin

monitor CK, myopathy sx: combo may incr. fluvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• fosaprepitant
Venclexta (venetoclax)

+

fosaprepitant

1 interaction

Monitor/Modify Tx

venetoclax + fosaprepitant

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• foscarnet
Venclexta (venetoclax)

+

foscarnet

1 interaction

Monitor/Modify Tx

venetoclax + foscarnet

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fosfomycin injection
Venclexta (venetoclax)

+

fosfomycin injection

1 interaction

Monitor/Modify Tx

venetoclax + fosfomycin injection

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• gepotidacin
Venclexta (venetoclax)

+

gepotidacin

1 interaction

Monitor/Modify Tx

venetoclax + gepotidacin

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• givinostat
Venclexta (venetoclax)

+

givinostat

1 interaction

Monitor/Modify Tx

venetoclax + givinostat

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (GI metabolism inhibited, additive effects)

• givosiran
Venclexta (venetoclax)

+

givosiran

1 interaction

Monitor/Modify Tx

venetoclax + givosiran

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited; givosiran effects on hepatic heme biosynthesis may reduce CYP450 enzyme activity)

• glimepiride
Venclexta (venetoclax)

+

glimepiride

1 interaction

Monitor/Modify Tx

venetoclax + glimepiride

monitor glucose: combo may incr. glimepiride levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

• goldenseal
Venclexta (venetoclax)

+

goldenseal

1 interaction

Monitor/Modify Tx

venetoclax + goldenseal

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• grazoprevir
Venclexta (venetoclax)

+

grazoprevir

1 interaction

Monitor/Modify Tx

venetoclax + grazoprevir

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• Haemophilus b vaccine
Venclexta (venetoclax)

+

Haemophilus b vaccine

1 interaction

Monitor/Modify Tx

venetoclax + Haemophilus b vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hepatitis A vaccine
Venclexta (venetoclax)

+

hepatitis A vaccine

1 interaction

Monitor/Modify Tx

venetoclax + hepatitis A vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hepatitis B vaccine
Venclexta (venetoclax)

+

hepatitis B vaccine

1 interaction

Monitor/Modify Tx

venetoclax + hepatitis B vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• human papillomavirus vaccine
Venclexta (venetoclax)

+

human papillomavirus vaccine

1 interaction

Monitor/Modify Tx

venetoclax + human papillomavirus vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hydroxychloroquine
Venclexta (venetoclax)

+

hydroxychloroquine

1 interaction

Monitor/Modify Tx

venetoclax + hydroxychloroquine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• hydroxyurea
Venclexta (venetoclax)

+

hydroxyurea

1 interaction

Monitor/Modify Tx

venetoclax + hydroxyurea

monitor CBC: combo may incr. risk of myelosuppression, serious infection (additive effects)

• influenza H5N1 vaccine
Venclexta (venetoclax)

+

influenza H5N1 vaccine

1 interaction

Monitor/Modify Tx

venetoclax + influenza H5N1 vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• influenza vaccine
Venclexta (venetoclax)

+

influenza vaccine

1 interaction

Monitor/Modify Tx

venetoclax + influenza vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• interferon beta 1a
Venclexta (venetoclax)

+

interferon beta 1a

1 interaction

Monitor/Modify Tx

venetoclax + interferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon beta 1b
Venclexta (venetoclax)

+

interferon beta 1b

1 interaction

Monitor/Modify Tx

venetoclax + interferon beta 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon gamma 1b
Venclexta (venetoclax)

+

interferon gamma 1b

1 interaction

Monitor/Modify Tx

venetoclax + interferon gamma 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• isoniazid
Venclexta (venetoclax)

+

isoniazid

1 interaction

Monitor/Modify Tx

venetoclax + isoniazid

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• Japanese encephalitis vaccine
Venclexta (venetoclax)

+

Japanese encephalitis vaccine

1 interaction

Monitor/Modify Tx

venetoclax + Japanese encephalitis vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• kratom
Venclexta (venetoclax)

+

kratom

1 interaction

Monitor/Modify Tx

venetoclax + kratom

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• larotrectinib
Venclexta (venetoclax)

+

larotrectinib

1 interaction

Monitor/Modify Tx

venetoclax + larotrectinib

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• lazertinib
Venclexta (venetoclax)

+

lazertinib

1 interaction

Monitor/Modify Tx

venetoclax + lazertinib

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• leflunomide
Venclexta (venetoclax)

+

leflunomide

1 interaction

Monitor/Modify Tx

venetoclax + leflunomide

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• linezolid
Venclexta (venetoclax)

+

linezolid

1 interaction

Monitor/Modify Tx

venetoclax + linezolid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lovastatin
Venclexta (venetoclax)

+

lovastatin

1 interaction

Monitor/Modify Tx

venetoclax + lovastatin

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• lovotibeglogene autotemcel
Venclexta (venetoclax)

+

lovotibeglogene autotemcel

1 interaction

Monitor/Modify Tx

venetoclax + lovotibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lurasidone
Venclexta (venetoclax)

+

lurasidone

1 interaction

Monitor/Modify Tx

venetoclax + lurasidone

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• lymphocyte immune globulin, anti-thymocyte globulin
Venclexta (venetoclax)

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

venetoclax + lymphocyte immune globulin, anti-thymocyte globulin

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• meningococcal vaccine
Venclexta (venetoclax)

+

meningococcal vaccine

1 interaction

Monitor/Modify Tx

venetoclax + meningococcal vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mercaptopurine
Venclexta (venetoclax)

+

mercaptopurine

1 interaction

Monitor/Modify Tx

venetoclax + mercaptopurine

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• mesalamine
Venclexta (venetoclax)

+

mesalamine

1 interaction

Monitor/Modify Tx

venetoclax + mesalamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine rectal
Venclexta (venetoclax)

+

mesalamine rectal

1 interaction

Monitor/Modify Tx

venetoclax + mesalamine rectal

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• methotrexate
Venclexta (venetoclax)

+

methotrexate

1 interaction

Monitor/Modify Tx

venetoclax + methotrexate

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• morphine
Venclexta (venetoclax)

+

morphine

1 interaction

Monitor/Modify Tx

venetoclax + morphine

monitor resp. rate, consider decr. dose of one or both drugs; give oral morphine at least 6h before venetoclax: combo may incr. morphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (gut P-gp-mediated transport inhibited)

• mycophenolate mofetil
Venclexta (venetoclax)

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

venetoclax + mycophenolate mofetil

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• mycophenolic acid
Venclexta (venetoclax)

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

venetoclax + mycophenolic acid

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• naldemedine
Venclexta (venetoclax)

+

naldemedine

1 interaction

Monitor/Modify Tx

venetoclax + naldemedine

give naldemedine at least 6h before venetoclax: combo may incr. naldemedine levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• nicardipine
Venclexta (venetoclax)

+

nicardipine

1 interaction

Monitor/Modify Tx

venetoclax + nicardipine

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• olsalazine
Venclexta (venetoclax)

+

olsalazine

1 interaction

Monitor/Modify Tx

venetoclax + olsalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• osilodrostat
Venclexta (venetoclax)

+

osilodrostat

1 interaction

Monitor/Modify Tx

venetoclax + osilodrostat

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• palbociclib
Venclexta (venetoclax)

+

palbociclib

1 interaction

Monitor/Modify Tx

venetoclax + palbociclib

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• pazopanib
Venclexta (venetoclax)

+

pazopanib

1 interaction

Monitor/Modify Tx

venetoclax + pazopanib

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• pegfilgrastim (G-CSF)
Venclexta (venetoclax)

+

pegfilgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

venetoclax + pegfilgrastim (G-CSF)

admin. pegfilgrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. pegfilgrastim efficacy (antagonistic effects)

• peginterferon alfa 2a
Venclexta (venetoclax)

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

venetoclax + peginterferon alfa 2a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• peginterferon beta 1a
Venclexta (venetoclax)

+

peginterferon beta 1a

1 interaction

Monitor/Modify Tx

venetoclax + peginterferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pentamidine
Venclexta (venetoclax)

+

pentamidine

1 interaction

Monitor/Modify Tx

venetoclax + pentamidine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• peppermint
Venclexta (venetoclax)

+

peppermint

1 interaction

Monitor/Modify Tx

venetoclax + peppermint

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• pneumococcal vaccine
Venclexta (venetoclax)

+

pneumococcal vaccine

1 interaction

Monitor/Modify Tx

venetoclax + pneumococcal vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• poliovirus vaccine
Venclexta (venetoclax)

+

poliovirus vaccine

1 interaction

Monitor/Modify Tx

venetoclax + poliovirus vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pretomanid
Venclexta (venetoclax)

+

pretomanid

1 interaction

Monitor/Modify Tx

venetoclax + pretomanid

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport possibly inhibited)

• proguanil
Venclexta (venetoclax)

+

proguanil

1 interaction

Monitor/Modify Tx

venetoclax + proguanil

monitor CBC, especially if concomitant renal impairment: combo may incr. risk of myelosuppression (additive effects)

• pyrimethamine
Venclexta (venetoclax)

+

pyrimethamine

1 interaction

Monitor/Modify Tx

venetoclax + pyrimethamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• remdesivir
Venclexta (venetoclax)

+

remdesivir

1 interaction

Monitor/Modify Tx

venetoclax + remdesivir

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• respiratory syncytial virus vaccine
Venclexta (venetoclax)

+

respiratory syncytial virus vaccine

1 interaction

Monitor/Modify Tx

venetoclax + respiratory syncytial virus vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• resveratrol
Venclexta (venetoclax)

+

resveratrol

1 interaction

Monitor/Modify Tx

venetoclax + resveratrol

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• ribavirin
Venclexta (venetoclax)

+

ribavirin

1 interaction

Monitor/Modify Tx

venetoclax + ribavirin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ritlecitinib
Venclexta (venetoclax)

+

ritlecitinib

1 interaction

Monitor/Modify Tx

venetoclax + ritlecitinib

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, additive effects)

• rituximab
Venclexta (venetoclax)

+

rituximab

1 interaction

Monitor/Modify Tx

venetoclax + rituximab

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• ruxolitinib topical
Venclexta (venetoclax)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

venetoclax + ruxolitinib topical

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• sargramostim (GM-CSF)
Venclexta (venetoclax)

+

sargramostim (GM-CSF)

1 interaction

Monitor/Modify Tx

venetoclax + sargramostim (GM-CSF)

admin. sargramostim >24h before or after myelosuppressive chemo: combo may decr. sargramostim efficacy (antagonistic effects)

• sarilumab
Venclexta (venetoclax)

+

sarilumab

1 interaction

Monitor/Modify Tx

venetoclax + sarilumab

monitor CBC: combo may decr. venetoclax levels, efficacy; may incr. risk of serious infection, myelosuppression (hepatic metabolism altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C; additive effects)

• satralizumab
Venclexta (venetoclax)

+

satralizumab

1 interaction

Monitor/Modify Tx

venetoclax + satralizumab

monitor CBC: combo may incr. risk of myelosuppression, serious infection (additive effects)

• sipuleucel-T
Venclexta (venetoclax)

+

sipuleucel-T

1 interaction

Monitor/Modify Tx

venetoclax + sipuleucel-T

consider decr. venetoclax dose or D/C during leukapheresis and sipuleucel-T admin.: combo may decr. efficacy of sipuleucel-T; may incr. risk of adverse effects (antagonistic effects; additive effects)

• sirolimus
Venclexta (venetoclax)

+

sirolimus

1 interaction

Monitor/Modify Tx

venetoclax + sirolimus

monitor sirolimus levels, CBC or give sirolimus at least 6h before venetoclax: combo may incr. sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (gut P-gp-mediated transport inhibited, additive effects)

• smallpox/mpox vaccine, live
Venclexta (venetoclax)

+

smallpox/ mpox vaccine, live

1 interaction

Monitor/Modify Tx

venetoclax + smallpox/ mpox vaccine, live

consider vaccinating at least 4wk before or 6mo after venetoclax tx: combo may result in inadequate vaccine response (immunosuppressive effects)

• spironolactone
Venclexta (venetoclax)

+

spironolactone

1 interaction

Monitor/Modify Tx

venetoclax + spironolactone

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism possibly inhibited)

• succimer
Venclexta (venetoclax)

+

succimer

1 interaction

Monitor/Modify Tx

venetoclax + succimer

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sulfasalazine
Venclexta (venetoclax)

+

sulfasalazine

1 interaction

Monitor/Modify Tx

venetoclax + sulfasalazine

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• tenofovir alafenamide
Venclexta (venetoclax)

+

tenofovir alafenamide

1 interaction

Monitor/Modify Tx

venetoclax + tenofovir alafenamide

if tenofovir alafenamide not admin. w/ cobicistat, monitor renal fxn and give tenofovir alafenamide at least 6h before venetoclax: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited)

• teplizumab
Venclexta (venetoclax)

+

teplizumab

1 interaction

Monitor/Modify Tx

venetoclax + teplizumab

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• teriflunomide
Venclexta (venetoclax)

+

teriflunomide

1 interaction

Monitor/Modify Tx

venetoclax + teriflunomide

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• thalidomide
Venclexta (venetoclax)

+

thalidomide

1 interaction

Monitor/Modify Tx

venetoclax + thalidomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tick-borne encephalitis vaccine
Venclexta (venetoclax)

+

tick-borne encephalitis vaccine

1 interaction

Monitor/Modify Tx

venetoclax + tick-borne encephalitis vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tocilizumab
Venclexta (venetoclax)

+

tocilizumab

1 interaction

Monitor/Modify Tx

venetoclax + tocilizumab

monitor CBC: combo may decr. venetoclax levels, efficacy; may incr. risk of serious infection, myelosuppression (hepatic metabolism altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes; additive effects)

• tofacitinib
Venclexta (venetoclax)

+

tofacitinib

1 interaction

Monitor/Modify Tx

venetoclax + tofacitinib

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• torsemide
Venclexta (venetoclax)

+

torsemide

1 interaction

Monitor/Modify Tx

venetoclax + torsemide

monitor renal fxn, BP: combo may incr. torsemide levels, risk of nephrotoxicity, hypotension, other adverse effects (hepatic metabolism inhibited)

• treosulfan
Venclexta (venetoclax)

+

treosulfan

1 interaction

Monitor/Modify Tx

venetoclax + treosulfan

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism possibly inhibited)

• typhoid vaccine
Venclexta (venetoclax)

+

typhoid vaccine

1 interaction

Monitor/Modify Tx

venetoclax + typhoid vaccine

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ubrogepant
Venclexta (venetoclax)

+

ubrogepant

1 interaction

Monitor/Modify Tx

venetoclax + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed; give ubrogepant at least 6h before venetoclax: combo may incr. ubrogepant levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• upadacitinib
Venclexta (venetoclax)

+

upadacitinib

1 interaction

Monitor/Modify Tx

venetoclax + upadacitinib

monitor CBC: combo may incr. risk of myelosuppression, serious infection (additive effects)

• valproic acid
Venclexta (venetoclax)

+

valproic acid

1 interaction

Monitor/Modify Tx

venetoclax + valproic acid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• vancomycin
Venclexta (venetoclax)

+

vancomycin

1 interaction

Monitor/Modify Tx

venetoclax + vancomycin

VANCOMYCIN IV: monitor CBC, especially w/ long-term vancomycin; VANCOMYCIN PO use OK: combo may incr. risk of myelosuppression (additive effects)

• viloxazine
Venclexta (venetoclax)

+

viloxazine

1 interaction

Monitor/Modify Tx

venetoclax + viloxazine

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• vonoprazan
Venclexta (venetoclax)

+

vonoprazan

1 interaction

Monitor/Modify Tx

venetoclax + vonoprazan

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• warfarin
Venclexta (venetoclax)

+

warfarin

1 interaction

Monitor/Modify Tx

venetoclax + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• zidovudine
Venclexta (venetoclax)

+

zidovudine

1 interaction

Monitor/Modify Tx

venetoclax + zidovudine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ziftomenib
Venclexta (venetoclax)

+

ziftomenib

1 interaction

Monitor/Modify Tx

venetoclax + ziftomenib

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• zileuton
Venclexta (venetoclax)

+

zileuton

1 interaction

Monitor/Modify Tx

venetoclax + zileuton

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• zoster vaccine, recombinant
Venclexta (venetoclax)

+

zoster vaccine, recombinant

1 interaction

Monitor/Modify Tx

venetoclax + zoster vaccine, recombinant

if possible, vaccinate at least 4wk before and after venetoclax tx: combo may result in inadequate vaccine response (immunosuppressive effects)

Caution Advised

• abatacept
Venclexta (venetoclax)

+

abatacept

1 interaction

Caution Advised

venetoclax + abatacept

caution advised: combo may incr. risk of serious infection (additive effects)

• adalimumab
Venclexta (venetoclax)

+

adalimumab

1 interaction

Caution Advised

venetoclax + adalimumab

caution advised: combo may incr. risk of serious infection (additive effects)

• anakinra
Venclexta (venetoclax)

+

anakinra

1 interaction

Caution Advised

venetoclax + anakinra

caution advised: combo may incr. risk of serious infection (additive effects)

• anifrolumab
Venclexta (venetoclax)

+

anifrolumab

1 interaction

Caution Advised

venetoclax + anifrolumab

caution advised: combo may incr. risk of serious infection (additive effects)

• armodafinil
Venclexta (venetoclax)

+

armodafinil

1 interaction

Caution Advised

venetoclax + armodafinil

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• artemether/lumefantrine
Venclexta (venetoclax)

+

artemether/ lumefantrine

1 interaction

Caution Advised

venetoclax + artemether/ lumefantrine

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• basiliximab
Venclexta (venetoclax)

+

basiliximab

1 interaction

Caution Advised

venetoclax + basiliximab

caution advised: combo may incr. risk of serious infection (additive effects)

• beclomethasone inhaled
Venclexta (venetoclax)

+

beclomethasone inhaled

1 interaction

Caution Advised

venetoclax + beclomethasone inhaled

caution advised: combo may incr. risk of serious infection (additive effects)

• beclomethasone nasal
Venclexta (venetoclax)

+

beclomethasone nasal

1 interaction

Caution Advised

venetoclax + beclomethasone nasal

caution advised: combo may incr. risk of serious infection (additive effects)

• belatacept
Venclexta (venetoclax)

+

belatacept

1 interaction

Caution Advised

venetoclax + belatacept

caution advised: combo may incr. risk of serious infection (additive effects)

• belimumab
Venclexta (venetoclax)

+

belimumab

1 interaction

Caution Advised

venetoclax + belimumab

caution advised: combo may incr. risk of serious infection (additive effects)

• belzutifan
Venclexta (venetoclax)

+

belzutifan

1 interaction

Caution Advised

venetoclax + belzutifan

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• betamethasone
Venclexta (venetoclax)

+

betamethasone

1 interaction

Caution Advised

venetoclax + betamethasone

caution advised: combo may incr. risk of serious infection (additive effects)

• bexarotene
Venclexta (venetoclax)

+

bexarotene

1 interaction

Caution Advised

venetoclax + bexarotene

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• bimekizumab
Venclexta (venetoclax)

+

bimekizumab

1 interaction

Caution Advised

venetoclax + bimekizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• brodalumab
Venclexta (venetoclax)

+

brodalumab

1 interaction

Caution Advised

venetoclax + brodalumab

caution advised: combo may incr. risk of serious infection (additive effects)

• budesonide
Venclexta (venetoclax)

+

budesonide

1 interaction

Caution Advised

venetoclax + budesonide

caution advised: combo may incr. risk of serious infection (additive effects)

• budesonide inhaled
Venclexta (venetoclax)

+

budesonide inhaled

1 interaction

Caution Advised

venetoclax + budesonide inhaled

caution advised: combo may incr. risk of serious infection (additive effects)

• budesonide nasal
Venclexta (venetoclax)

+

budesonide nasal

1 interaction

Caution Advised

venetoclax + budesonide nasal

caution advised: combo may incr. risk of serious infection (additive effects)

• budesonide rectal
Venclexta (venetoclax)

+

budesonide rectal

1 interaction

Caution Advised

venetoclax + budesonide rectal

caution advised: combo may incr. risk of serious infection (additive effects)

• canakinumab
Venclexta (venetoclax)

+

canakinumab

1 interaction

Caution Advised

venetoclax + canakinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• certolizumab pegol
Venclexta (venetoclax)

+

certolizumab pegol

1 interaction

Caution Advised

venetoclax + certolizumab pegol

caution advised: combo may incr. risk of serious infection (additive effects)

• clobazam
Venclexta (venetoclax)

+

clobazam

1 interaction

Caution Advised

venetoclax + clobazam

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• clobetasol ophthalmic
Venclexta (venetoclax)

+

clobetasol ophthalmic

1 interaction

Caution Advised

venetoclax + clobetasol ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• coccidioides immitis skin test antigen
Venclexta (venetoclax)

+

coccidioides immitis skin test antigen

1 interaction

Caution Advised

venetoclax + coccidioides immitis skin test antigen

caution advised: combo may interfere with test results (antagonistic effects)

• corticotropin
Venclexta (venetoclax)

+

corticotropin

1 interaction

Caution Advised

venetoclax + corticotropin

caution advised: combo may incr. risk of serious infection (additive effects)

• cortisone
Venclexta (venetoclax)

+

cortisone

1 interaction

Caution Advised

venetoclax + cortisone

caution advised: combo may incr. risk of serious infection (additive effects)

• crovalimab
Venclexta (venetoclax)

+

crovalimab

1 interaction

Caution Advised

venetoclax + crovalimab

caution advised: combo may incr. risk of serious infection (additive effects)

• danshen
Venclexta (venetoclax)

+

danshen

1 interaction

Caution Advised

venetoclax + danshen

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• deflazacort
Venclexta (venetoclax)

+

deflazacort

1 interaction

Caution Advised

venetoclax + deflazacort

caution advised: combo may incr. risk of serious infection (additive effects)

• delgocitinib topical
Venclexta (venetoclax)

+

delgocitinib topical

1 interaction

Caution Advised

venetoclax + delgocitinib topical

caution advised: combo may incr. risk of serious infection (additive effects)

• deucravacitinib
Venclexta (venetoclax)

+

deucravacitinib

1 interaction

Caution Advised

venetoclax + deucravacitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• dexamethasone
Venclexta (venetoclax)

+

dexamethasone

1 interaction

Caution Advised

venetoclax + dexamethasone

caution advised: combo may decr. venetoclax levels, efficacy; may incr. risk of serious infection (hepatic metabolism induced; additive effects)

• dexamethasone ophthalmic
Venclexta (venetoclax)

+

dexamethasone ophthalmic

1 interaction

Caution Advised

venetoclax + dexamethasone ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• dicloxacillin
Venclexta (venetoclax)

+

dicloxacillin

1 interaction

Caution Advised

venetoclax + dicloxacillin

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• difluprednate ophthalmic
Venclexta (venetoclax)

+

difluprednate ophthalmic

1 interaction

Caution Advised

venetoclax + difluprednate ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• dimethyl fumarate
Venclexta (venetoclax)

+

dimethyl fumarate

1 interaction

Caution Advised

venetoclax + dimethyl fumarate

caution advised: combo may incr. risk of serious infection (additive effects)

• dinutuximab
Venclexta (venetoclax)

+

dinutuximab

1 interaction

Caution Advised

venetoclax + dinutuximab

caution advised: combo may incr. risk of serious infection (additive effects)

• diroximel fumarate
Venclexta (venetoclax)

+

diroximel fumarate

1 interaction

Caution Advised

venetoclax + diroximel fumarate

caution advised: combo may incr. risk of serious infection (additive effects)

• dupilumab
Venclexta (venetoclax)

+

dupilumab

1 interaction

Caution Advised

venetoclax + dupilumab

caution advised: combo may incr. risk of serious infection (additive effects)

• echinacea
Venclexta (venetoclax)

+

echinacea

1 interaction

Caution Advised

venetoclax + echinacea

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• eculizumab
Venclexta (venetoclax)

+

eculizumab

1 interaction

Caution Advised

venetoclax + eculizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• efgartigimod alfa
Venclexta (venetoclax)

+

efgartigimod alfa

1 interaction

Caution Advised

venetoclax + efgartigimod alfa

caution advised: combo may incr. risk of serious infection (additive effects)

• elafibranor
Venclexta (venetoclax)

+

elafibranor

1 interaction

Caution Advised

venetoclax + elafibranor

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• emapalumab
Venclexta (venetoclax)

+

emapalumab

1 interaction

Caution Advised

venetoclax + emapalumab

caution advised: combo may incr. risk of serious infection (additive effects)

• eslicarbazepine acetate
Venclexta (venetoclax)

+

eslicarbazepine acetate

1 interaction

Caution Advised

venetoclax + eslicarbazepine acetate

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• etanercept
Venclexta (venetoclax)

+

etanercept

1 interaction

Caution Advised

venetoclax + etanercept

caution advised: combo may incr. risk of serious infection (additive effects)

• felbamate
Venclexta (venetoclax)

+

felbamate

1 interaction

Caution Advised

venetoclax + felbamate

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• fingolimod
Venclexta (venetoclax)

+

fingolimod

1 interaction

Caution Advised

venetoclax + fingolimod

caution advised during and x2mo after fingolimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• fludrocortisone
Venclexta (venetoclax)

+

fludrocortisone

1 interaction

Caution Advised

venetoclax + fludrocortisone

caution advised: combo may incr. risk of serious infection (additive effects)

• flunisolide nasal
Venclexta (venetoclax)

+

flunisolide nasal

1 interaction

Caution Advised

venetoclax + flunisolide nasal

caution advised: combo may incr. risk of serious infection (additive effects)

• fluocinolone intravitreal
Venclexta (venetoclax)

+

fluocinolone intravitreal

1 interaction

Caution Advised

venetoclax + fluocinolone intravitreal

caution advised: combo may incr. risk of serious infection (additive effects)

• fluorometholone ophthalmic
Venclexta (venetoclax)

+

fluorometholone ophthalmic

1 interaction

Caution Advised

venetoclax + fluorometholone ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• fluticasone furoate
Venclexta (venetoclax)

+

fluticasone furoate

1 interaction

Caution Advised

venetoclax + fluticasone furoate

caution advised: combo may incr. risk of serious infection (additive effects)

• fluticasone propionate
Venclexta (venetoclax)

+

fluticasone propionate

1 interaction

Caution Advised

venetoclax + fluticasone propionate

caution advised: combo may incr. risk of serious infection (additive effects)

• garlic
Venclexta (venetoclax)

+

garlic

1 interaction

Caution Advised

venetoclax + garlic

caution advised w/ supplemental garlic; dietary intake OK: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• ginseng, Asian
Venclexta (venetoclax)

+

ginseng, Asian

1 interaction

Caution Advised

venetoclax + ginseng, Asian

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• glycerol phenylbutyrate
Venclexta (venetoclax)

+

glycerol phenylbutyrate

1 interaction

Caution Advised

venetoclax + glycerol phenylbutyrate

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• golimumab
Venclexta (venetoclax)

+

golimumab

1 interaction

Caution Advised

venetoclax + golimumab

caution advised: combo may incr. risk of serious infection (additive effects)

• griseofulvin
Venclexta (venetoclax)

+

griseofulvin

1 interaction

Caution Advised

venetoclax + griseofulvin

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• guselkumab
Venclexta (venetoclax)

+

guselkumab

1 interaction

Caution Advised

venetoclax + guselkumab

caution advised: combo may incr. risk of serious infection (additive effects)

• hydrocortisone
Venclexta (venetoclax)

+

hydrocortisone

1 interaction

Caution Advised

venetoclax + hydrocortisone

caution advised: combo may incr. risk of serious infection (additive effects)

• hydrocortisone ophthalmic
Venclexta (venetoclax)

+

hydrocortisone ophthalmic

1 interaction

Caution Advised

venetoclax + hydrocortisone ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• inebilizumab
Venclexta (venetoclax)

+

inebilizumab

1 interaction

Caution Advised

venetoclax + inebilizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• infliximab
Venclexta (venetoclax)

+

infliximab

1 interaction

Caution Advised

venetoclax + infliximab

caution advised: combo may incr. risk of serious infection (additive effects)

• iptacopan
Venclexta (venetoclax)

+

iptacopan

1 interaction

Caution Advised

venetoclax + iptacopan

caution advised: combo may incr. risk of serious infection (additive effects)

• ixekizumab
Venclexta (venetoclax)

+

ixekizumab

1 interaction

Caution Advised

venetoclax + ixekizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• lebrikizumab
Venclexta (venetoclax)

+

lebrikizumab

1 interaction

Caution Advised

venetoclax + lebrikizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• lomustine
Venclexta (venetoclax)

+

lomustine

1 interaction

Caution Advised

venetoclax + lomustine

caution advised: combo may incr. risk of serious infection (additive effects)

• loteprednol ophthalmic
Venclexta (venetoclax)

+

loteprednol ophthalmic

1 interaction

Caution Advised

venetoclax + loteprednol ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• meropenem
Venclexta (venetoclax)

+

meropenem

1 interaction

Caution Advised

venetoclax + meropenem

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism possibly induced)

• methylprednisolone
Venclexta (venetoclax)

+

methylprednisolone

1 interaction

Caution Advised

venetoclax + methylprednisolone

caution advised: combo may incr. risk of serious infection (additive effects)

• mirikizumab
Venclexta (venetoclax)

+

mirikizumab

1 interaction

Caution Advised

venetoclax + mirikizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• mitoxantrone
Venclexta (venetoclax)

+

mitoxantrone

1 interaction

Caution Advised

venetoclax + mitoxantrone

caution advised: combo may incr. risk of serious infection (additive effects)

• mobocertinib
Venclexta (venetoclax)

+

mobocertinib

1 interaction

Caution Advised

venetoclax + mobocertinib

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• mometasone implant
Venclexta (venetoclax)

+

mometasone implant

1 interaction

Caution Advised

venetoclax + mometasone implant

caution advised: combo may incr. risk of serious infection (additive effects)

• mometasone inhaled
Venclexta (venetoclax)

+

mometasone inhaled

1 interaction

Caution Advised

venetoclax + mometasone inhaled

caution advised: combo may incr. risk of serious infection (additive effects)

• mometasone nasal
Venclexta (venetoclax)

+

mometasone nasal

1 interaction

Caution Advised

venetoclax + mometasone nasal

caution advised: combo may incr. risk of serious infection (additive effects)

• monomethyl fumarate
Venclexta (venetoclax)

+

monomethyl fumarate

1 interaction

Caution Advised

venetoclax + monomethyl fumarate

caution advised: combo may incr. risk of serious infection (additive effects)

• mosunetuzumab
Venclexta (venetoclax)

+

mosunetuzumab

1 interaction

Caution Advised

venetoclax + mosunetuzumab

caution advised: combo may incr. risk of serious infection (additive effects)

• nadofaragene firadenovec intravesical
Venclexta (venetoclax)

+

nadofaragene firadenovec intravesical

1 interaction

Caution Advised

venetoclax + nadofaragene firadenovec intravesical

caution advised: combo may incr. risk of disseminated adenovirus infection (immunosuppressive effects)

• narsoplimab
Venclexta (venetoclax)

+

narsoplimab

1 interaction

Caution Advised

venetoclax + narsoplimab

caution advised: combo may incr. risk of serious infection (additive effects)

• natalizumab
Venclexta (venetoclax)

+

natalizumab

1 interaction

Caution Advised

venetoclax + natalizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• nevirapine
Venclexta (venetoclax)

+

nevirapine

1 interaction

Caution Advised

venetoclax + nevirapine

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• nipocalimab
Venclexta (venetoclax)

+

nipocalimab

1 interaction

Caution Advised

venetoclax + nipocalimab

caution advised: combo may incr. risk of serious infection (additive effects)

• obinutuzumab
Venclexta (venetoclax)

+

obinutuzumab

1 interaction

Caution Advised

venetoclax + obinutuzumab

caution advised: combo may incr. risk of serious infection (additive effects)

• ocrelizumab
Venclexta (venetoclax)

+

ocrelizumab

1 interaction

Caution Advised

venetoclax + ocrelizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• odevixibat
Venclexta (venetoclax)

+

odevixibat

1 interaction

Caution Advised

venetoclax + odevixibat

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• ofatumumab
Venclexta (venetoclax)

+

ofatumumab

1 interaction

Caution Advised

venetoclax + ofatumumab

caution advised: combo may incr. risk of serious infection (additive effects)

• olutasidenib
Venclexta (venetoclax)

+

olutasidenib

1 interaction

Caution Advised

venetoclax + olutasidenib

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism possibly induced)

• omaveloxolone
Venclexta (venetoclax)

+

omaveloxolone

1 interaction

Caution Advised

venetoclax + omaveloxolone

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• oxcarbazepine
Venclexta (venetoclax)

+

oxcarbazepine

1 interaction

Caution Advised

venetoclax + oxcarbazepine

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• ozanimod
Venclexta (venetoclax)

+

ozanimod

1 interaction

Caution Advised

venetoclax + ozanimod

caution advised during and x3mo after ozanimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• pegcetacoplan
Venclexta (venetoclax)

+

pegcetacoplan

1 interaction

Caution Advised

venetoclax + pegcetacoplan

caution advised: combo may incr. risk of serious infection (additive effects)

• pentostatin
Venclexta (venetoclax)

+

pentostatin

1 interaction

Caution Advised

venetoclax + pentostatin

caution advised: combo may incr. risk of serious infection (additive effects)

• perampanel
Venclexta (venetoclax)

+

perampanel

1 interaction

Caution Advised

venetoclax + perampanel

caution advised if on perampanel 12 mg/day: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• pioglitazone
Venclexta (venetoclax)

+

pioglitazone

1 interaction

Caution Advised

venetoclax + pioglitazone

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• ponesimod
Venclexta (venetoclax)

+

ponesimod

1 interaction

Caution Advised

venetoclax + ponesimod

caution advised during and x1-2wk after ponesimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• pozelimab
Venclexta (venetoclax)

+

pozelimab

1 interaction

Caution Advised

venetoclax + pozelimab

caution advised: combo may incr. risk of serious infection (additive effects)

• prednisolone
Venclexta (venetoclax)

+

prednisolone

1 interaction

Caution Advised

venetoclax + prednisolone

caution advised: combo may incr. risk of serious infection (additive effects)

• prednisolone ophthalmic
Venclexta (venetoclax)

+

prednisolone ophthalmic

1 interaction

Caution Advised

venetoclax + prednisolone ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• prednisone
Venclexta (venetoclax)

+

prednisone

1 interaction

Caution Advised

venetoclax + prednisone

caution advised: combo may decr. venetoclax levels, efficacy; may incr. risk of serious infection (hepatic metabolism induced; additive effects)

• ravulizumab
Venclexta (venetoclax)

+

ravulizumab

1 interaction

Caution Advised

venetoclax + ravulizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• rilonacept
Venclexta (venetoclax)

+

rilonacept

1 interaction

Caution Advised

venetoclax + rilonacept

caution advised: combo may incr. risk of serious infection (additive effects)

• risankizumab
Venclexta (venetoclax)

+

risankizumab

1 interaction

Caution Advised

venetoclax + risankizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• rozanolixizumab
Venclexta (venetoclax)

+

rozanolixizumab

1 interaction

Caution Advised

venetoclax + rozanolixizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• rufinamide
Venclexta (venetoclax)

+

rufinamide

1 interaction

Caution Advised

venetoclax + rufinamide

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• secukinumab
Venclexta (venetoclax)

+

secukinumab

1 interaction

Caution Advised

venetoclax + secukinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• selinexor
Venclexta (venetoclax)

+

selinexor

1 interaction

Caution Advised

venetoclax + selinexor

caution advised: combo may incr. risk of serious infection (additive effects)

• sibeprenlimab
Venclexta (venetoclax)

+

sibeprenlimab

1 interaction

Caution Advised

venetoclax + sibeprenlimab

caution advised: combo may incr. risk of serious infection (additive effects)

• siltuximab
Venclexta (venetoclax)

+

siltuximab

1 interaction

Caution Advised

venetoclax + siltuximab

caution advised: combo may incr. risk of serious infection (additive effects)

• siponimod
Venclexta (venetoclax)

+

siponimod

1 interaction

Caution Advised

venetoclax + siponimod

caution advised during and x3-4wk after siponimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• spesolimab
Venclexta (venetoclax)

+

spesolimab

1 interaction

Caution Advised

venetoclax + spesolimab

caution advised: combo may incr. risk of serious infection (additive effects)

• sutimlimab
Venclexta (venetoclax)

+

sutimlimab

1 interaction

Caution Advised

venetoclax + sutimlimab

caution advised: combo may incr. risk of serious infection (additive effects)

• suzetrigine
Venclexta (venetoclax)

+

suzetrigine

1 interaction

Caution Advised

venetoclax + suzetrigine

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• tazemetostat
Venclexta (venetoclax)

+

tazemetostat

1 interaction

Caution Advised

venetoclax + tazemetostat

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• tecovirimat
Venclexta (venetoclax)

+

tecovirimat

1 interaction

Caution Advised

venetoclax + tecovirimat

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• telotristat ethyl
Venclexta (venetoclax)

+

telotristat ethyl

1 interaction

Caution Advised

venetoclax + telotristat ethyl

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• tezepelumab
Venclexta (venetoclax)

+

tezepelumab

1 interaction

Caution Advised

venetoclax + tezepelumab

caution advised: combo may incr. risk of serious infection (possible additive effects)

• thioguanine
Venclexta (venetoclax)

+

thioguanine

1 interaction

Caution Advised

venetoclax + thioguanine

caution advised: combo may incr. risk of serious infection (additive effects)

• tildrakizumab
Venclexta (venetoclax)

+

tildrakizumab

1 interaction

Caution Advised

venetoclax + tildrakizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• topiramate
Venclexta (venetoclax)

+

topiramate

1 interaction

Caution Advised

venetoclax + topiramate

caution advised, especially w/ topiramate doses >200 mg/day: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• tovorafenib
Venclexta (venetoclax)

+

tovorafenib

1 interaction

Caution Advised

venetoclax + tovorafenib

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• trabectedin
Venclexta (venetoclax)

+

trabectedin

1 interaction

Caution Advised

venetoclax + trabectedin

caution advised: combo may incr. risk of serious infection (additive effects)

• tralokinumab
Venclexta (venetoclax)

+

tralokinumab

1 interaction

Caution Advised

venetoclax + tralokinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• triamcinolone
Venclexta (venetoclax)

+

triamcinolone

1 interaction

Caution Advised

venetoclax + triamcinolone

caution advised: combo may incr. risk of serious infection (additive effects)

• tuberculin purified protein derivative
Venclexta (venetoclax)

+

tuberculin purified protein derivative

1 interaction

Caution Advised

venetoclax + tuberculin purified protein derivative

caution advised during and x5-6wk after venetoclax tx: combo may interfere with test results (antagonistic effects)

• ublituximab
Venclexta (venetoclax)

+

ublituximab

1 interaction

Caution Advised

venetoclax + ublituximab

caution advised: combo may incr. risk of serious infection (additive effects)

• ustekinumab
Venclexta (venetoclax)

+

ustekinumab

1 interaction

Caution Advised

venetoclax + ustekinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• vaborbactam
Venclexta (venetoclax)

+

vaborbactam

1 interaction

Caution Advised

venetoclax + vaborbactam

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism possibly induced)

• vamorolone
Venclexta (venetoclax)

+

vamorolone

1 interaction

Caution Advised

venetoclax + vamorolone

caution advised: combo may decr. venetoclax levels, efficacy; may incr. risk of serious infection (hepatic metabolism possibly induced; additive effects)

• vedolizumab
Venclexta (venetoclax)

+

vedolizumab

1 interaction

Caution Advised

venetoclax + vedolizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• vilobelimab
Venclexta (venetoclax)

+

vilobelimab

1 interaction

Caution Advised

venetoclax + vilobelimab

caution advised: combo may incr. risk of serious infection (additive effects)

• vinblastine
Venclexta (venetoclax)

+

vinblastine

1 interaction

Caution Advised

venetoclax + vinblastine

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• vorasidenib
Venclexta (venetoclax)

+

vorasidenib

1 interaction

Caution Advised

venetoclax + vorasidenib

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism possibly induced)

• zanubrutinib
Venclexta (venetoclax)

+

zanubrutinib

1 interaction

Caution Advised

venetoclax + zanubrutinib

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• zilucoplan
Venclexta (venetoclax)

+

zilucoplan

1 interaction

Caution Advised

venetoclax + zilucoplan

caution advised: combo may incr. risk of serious infection (additive effects)